Discovery and Characterization of ZL-2201, a Potent, Highly Selective, and Orally Bioavailable Small-molecule DNA-PK Inhibitor.
Shruti LalNeil H BholaBee-Chun SunYuping ChenTom HuangVivian MortonKevin X ChenShanghua XiaHaoyu ZhangNehal S ParikhQiuping YeO Petter VeibyDavid I BellovinYuhua JiPublished in: Cancer research communications (2023)
ZL-2201, a potent and selective DNA-PK inhibitor, can target tumor models in combination with DNA DSB-inducing agents such as radiation or doxorubicin, with potential to improve recurrent therapies in the clinic.